Troxyca Er is a drug owned by Pfizer Inc. It is protected by 2 US drug patents filed in 2016 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Dec 12, 2027. Details of Troxyca Er's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7815934 | Sequestering subunit and related compositions and methods |
Dec, 2027
(2 years from now) | Active |
| US8685443 | Sequestering subunit and related compositions and methods |
Jul, 2025
(6 months from now) | Active |
FDA has granted several exclusivities to Troxyca Er. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Troxyca Er, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Troxyca Er.
Exclusivity Information
Troxyca Er holds 1 exclusivities. All of its exclusivities have expired in 2019. Details of Troxyca Er's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Aug 19, 2019 |
US patents provide insights into the exclusivity only within the United States, but Troxyca Er is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Troxyca Er's family patents as well as insights into ongoing legal events on those patents.
Troxyca Er's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Troxyca Er's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Dec 12, 2027 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Troxyca Er Generics:
There are no approved generic versions for Troxyca Er as of now.
Alternative Brands for Troxyca Er
Troxyca Er which is used for managing severe, long-term pain that requires daily opioid treatment., has several other brand drugs in the same treatment category . Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Alpharma Pharms |
| |||
About Troxyca Er
Troxyca Er is a drug owned by Pfizer Inc. It is used for managing severe, long-term pain that requires daily opioid treatment. Troxyca Er uses Naltrexone Hydrochloride; Oxycodone Hydrochloride as an active ingredient. Troxyca Er was launched by Pfizer in 2016.
Approval Date:
Troxyca Er was approved by FDA for market use on 19 August, 2016.
Active Ingredient:
Troxyca Er uses Naltrexone Hydrochloride; Oxycodone Hydrochloride as the active ingredient. Check out other Drugs and Companies using Naltrexone Hydrochloride; Oxycodone Hydrochloride ingredient
Treatment:
Troxyca Er is used for managing severe, long-term pain that requires daily opioid treatment.
Dosage:
Troxyca Er is available in capsule, extended release form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 1.2MG;10MG | CAPSULE, EXTENDED RELEASE | Discontinued | ORAL |
| 3.6MG;30MG | CAPSULE, EXTENDED RELEASE | Discontinued | ORAL |
| 7.2MG;60MG | CAPSULE, EXTENDED RELEASE | Discontinued | ORAL |
| 2.4MG;20MG | CAPSULE, EXTENDED RELEASE | Discontinued | ORAL |
| 4.8MG;40MG | CAPSULE, EXTENDED RELEASE | Discontinued | ORAL |
| 9.6MG;80MG | CAPSULE, EXTENDED RELEASE | Discontinued | ORAL |